➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Colorcon
Harvard Business School
Moodys
McKesson

Last Updated: June 3, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Bardoxolone methyl


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Bardoxolone methyl?

Bardoxolone methyl is an investigational drug.

There have been 27 clinical trials for Bardoxolone methyl. The most recent clinical trial was a Phase 2 trial, which was initiated on May 30th 2018.

The most common disease conditions in clinical trials are Kidney Diseases, Renal Insufficiency, Chronic, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Reata Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd., and Kyowa Hakko Kirin Company, Limited.

There are sixteen US patents protecting this investigational drug and fifty-nine international patents.

Recent Clinical Trials for Bardoxolone methyl
TitleSponsorPhase
Phase I Study of RTA 402 in Obese AdultsKyowa Kirin Co., Ltd.Phase 1
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCONReata Pharmaceuticals, Inc.Phase 3
A Clinical Pharmacology Study of Bardoxolone Methyl in Healthy AdultsKyowa Kirin Co., Ltd.Phase 1

See all Bardoxolone methyl clinical trials

Clinical Trial Summary for Bardoxolone methyl

Top disease conditions for Bardoxolone methyl
Top clinical trial sponsors for Bardoxolone methyl

See all Bardoxolone methyl clinical trials

US Patents for Bardoxolone methyl

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Bardoxolone methyl   Start Trial Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole Trustees of Dartmouth College (Hanover, NH)   Start Trial
Bardoxolone methyl   Start Trial Terpenoid derivatives Daiichi Sankyo Company, Limited (Chuo-ku, JP)   Start Trial
Bardoxolone methyl   Start Trial CDDO-compounds and combination therapies thereof The Trustees of Dartmouth College (Hanover, NH) Board of Regents, The University of Texas System (Austin, TX)   Start Trial
Bardoxolone methyl   Start Trial CDDO-compounds and combination therapies thereof Board of Regents, The University of Texas System (Austin, TX) The Trustees of Dartmouth College (Hanover, NH)   Start Trial
Bardoxolone methyl   Start Trial Antioxidant inflammation modulators: novel derivatives of oleanolic acid Reata Pharmaceuticals, Inc. (Irving, TX)   Start Trial
Bardoxolone methyl   Start Trial Antioxidant inflammation modulators: novel derivatives of oleanolic acid Reata Pharmaceuticals, Inc. (Irving, TX)   Start Trial
Bardoxolone methyl   Start Trial Triterpenoids and compositions containing the same Trustees of Dartmouth College (Hanover, NH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Bardoxolone methyl

Drugname Country Document Number Estimated Expiration Related US Patent
Bardoxolone methyl World Intellectual Property Organization (WIPO) 2016033132 2034-08-26   Start Trial
Bardoxolone methyl European Patent Office 2977381 2033-03-19   Start Trial
Bardoxolone methyl Japan 6328102 2033-03-19   Start Trial
Bardoxolone methyl Japan WO2014148455 2033-03-19   Start Trial
Bardoxolone methyl Taiwan 201514192 2033-03-19   Start Trial
Bardoxolone methyl World Intellectual Property Organization (WIPO) 2014148455 2033-03-19   Start Trial
Bardoxolone methyl Australia 4324602 2020-11-28   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Baxter
Moodys
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.